JP2022534724A - がんを治療するためのｐｒｇ４の使用 - Google Patents

がんを治療するためのｐｒｇ４の使用 Download PDF

Info

Publication number
JP2022534724A
JP2022534724A JP2021570319A JP2021570319A JP2022534724A JP 2022534724 A JP2022534724 A JP 2022534724A JP 2021570319 A JP2021570319 A JP 2021570319A JP 2021570319 A JP2021570319 A JP 2021570319A JP 2022534724 A JP2022534724 A JP 2022534724A
Authority
JP
Japan
Prior art keywords
cancer
prg4
rhprg4
cells
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570319A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020247440A5 (https=
JP2022534724A5 (https=
Inventor
ボンニ，シリン
サルカール，アヌシ
シュミット，タンニン，エー．
サリバン，ベンジャミン，ディー．
Original Assignee
ルブリス，エルエルシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルブリス，エルエルシー． filed Critical ルブリス，エルエルシー．
Publication of JP2022534724A publication Critical patent/JP2022534724A/ja
Publication of JPWO2020247440A5 publication Critical patent/JPWO2020247440A5/ja
Publication of JP2022534724A5 publication Critical patent/JP2022534724A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021570319A 2019-06-03 2020-06-03 がんを治療するためのｐｒｇ４の使用 Pending JP2022534724A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962856514P 2019-06-03 2019-06-03
US62/856,514 2019-06-03
US202063013427P 2020-04-21 2020-04-21
US63/013,427 2020-04-21
PCT/US2020/035841 WO2020247440A1 (en) 2019-06-03 2020-06-03 Use of prg4 to treat cancer

Publications (3)

Publication Number Publication Date
JP2022534724A true JP2022534724A (ja) 2022-08-03
JPWO2020247440A5 JPWO2020247440A5 (https=) 2023-06-07
JP2022534724A5 JP2022534724A5 (https=) 2023-06-07

Family

ID=73652433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570319A Pending JP2022534724A (ja) 2019-06-03 2020-06-03 がんを治療するためのｐｒｇ４の使用

Country Status (5)

Country Link
US (1) US20220332839A1 (https=)
EP (1) EP3976085A4 (https=)
JP (1) JP2022534724A (https=)
CN (1) CN114173805A (https=)
WO (1) WO2020247440A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000022636A1 (it) * 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
KR102763607B1 (ko) * 2021-10-05 2025-02-07 주식회사 인게니움테라퓨틱스 자연살해 세포의 활성 향상용 조성물
CN115125207B (zh) * 2022-08-01 2023-05-02 威海见生生物技术有限公司 一种诱导干细胞体外定向分化的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539189A (ja) * 2013-11-26 2016-12-15 ルブリス，エルエルシー． 細胞間相互作用を阻害するための組成物及び方法
JP2018505867A (ja) * 2015-01-26 2018-03-01 ルブリス，エルエルシー． 抗炎症剤としてのｐｒｇ４の使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060935A1 (en) * 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539189A (ja) * 2013-11-26 2016-12-15 ルブリス，エルエルシー． 細胞間相互作用を阻害するための組成物及び方法
JP2018505867A (ja) * 2015-01-26 2018-03-01 ルブリス，エルエルシー． 抗炎症剤としてのｐｒｇ４の使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. 14, no. 7, JPN6024017234, July 2019 (2019-07-01), pages 0219697, ISSN: 0005315250 *

Also Published As

Publication number Publication date
EP3976085A1 (en) 2022-04-06
US20220332839A1 (en) 2022-10-20
WO2020247440A1 (en) 2020-12-10
EP3976085A4 (en) 2023-04-05
CN114173805A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
AU2021204818A1 (en) Methods to eliminate cancer stem cells by targeting cd47
Liu et al. CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells
Nummela et al. Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells
EP2822573B1 (en) Treatment of cancer
Jia et al. Yes-associated protein contributes to the development of human cutaneous squamous cell carcinoma via activation of RAS
US20100074897A1 (en) Methods and Compositions related to HIF-1 alpha
US20200062862A1 (en) Methods and compositions for prognosis, diagnosis, and treatment of adam8-expressing cancer
JP6426001B2 (ja) 神経膠腫を治療するための組成物および方法
JP2022534724A (ja) がんを治療するためのｐｒｇ４の使用
Lv et al. Human peritoneal mesothelial cell transformation into myofibroblasts in response to TGF-ß1 in vitro
US20160237158A1 (en) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
Kwon et al. Extra domain A‐containing fibronectin expression in Spin90‐deficient fibroblasts mediates cancer‐stroma interaction and promotes breast cancer progression
Choi et al. Fc-saxatilin inhibits VEGF-induced permeability by regulating claudin-5 expression in human brain microvascular endothelial cells
Chen et al. SNF5, a core subunit of SWI/SNF complex, regulates melanoma cancer cell growth, metastasis, and immune escape in response to matrix stiffness
US10626397B2 (en) Therapeutic compositions for breast cancer containing protein kinase D1 inhibitor
KR20140131827A (ko) ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도
Salo et al. Antibodies blocking adhesion and matrix binding domains of laminin‐332 inhibit tumor growth and metastasis in vivo
KR102181813B1 (ko) 단백질 카이네이즈 d1 저해제를 포함하는 유방암 치료제 조성물
US20170253882A1 (en) Target of vgsc beta-3 protein for prevention, treatment and diagnostic detection of cancers
KR20140144934A (ko) Ｃｔｈｒｃ１의 발현 및 활성 억제제를 유효성분으로 포함하는 췌장암 치료 및 전이억제용 조성물
Marianantoni Study of role of sulphated proteoglycans in cancer
Meghnani RAGE (Receptor for Advanced Glycation End Products) in melanoma progression
Bascetta Mutant p53 alters tumor microenvironment by reprogramming the cancer cell secretome via miR-30d
Yuzhalin Proteomic profiling of metastatic matrisome reveals citrullination as a marker of colorectal liver metastasis
EP2440238A1 (en) Methods of treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241202